Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test clues could sharpen cervical cancer treatment

NCT ID NCT05673252

Knowledge-focused Sponsor: University of Campania Luigi Vanvitelli Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This study looks at whether simple blood tests can help predict how aggressive cervical cancer might be. Researchers will measure inflammatory markers in blood samples from women with early-stage cervical cancer and compare them to tumor characteristics. The goal is to see if these markers could help doctors better classify risk and choose the most appropriate treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Venous blood sample and biopsy
What this could lead to
If inflammatory markers predict risk, doctors could better tailor treatment for cervical cancer patients.
What could go wrong
This is an observational study, so it can't prove cause and effect. Results may not change practice without further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 128 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2023

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with histological diagnosis of cervical cancer undergoing surgical intervention who performed full-body CT-scan 30 days before enrollment.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * At least 18-year-old patients. * Patients histologically diagnosed with cervical cancer (squamous cell carcinoma or adenocarcinoma HPV- associated) * Patients with (2018 FIGO) stage ≤ IB2 ("Early Cervical Cancer") * Patients undergoing full-body CT-scan 30 days before enrollment. Exclusion Criteria: * Patients unfit to plead * Patients with chronic inflammatory diseases (IBDs; rheumatic conditions) * Synchronous tumors or cancer diagnosis in the previous 3 years * Patients undergoing steroid therapy in the last 30 days prior to recruitment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cervical cancer

Contacts and locations

Locations

  • Università degli Studi della Campania Luigi Vanvitelli

    Naples, Naples, 80138, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.